Deferred Revenues (Tables)

12 Months Ended

Sep. 30, 2013

The following table sets forth as of September 30, 2013 and 2012 the net deferred revenue balances for NUEDEXTA product shipments and the Company’s sale of future Abreva^® royalty rights to Drug Royalty USA.


	NUEDEXTA Product Shipments, Net			Drug Royalty USA Agreement			Total
Net deferred revenues as of October 1, 2012	$	—		$	4,049,318		$	4,049,318
Shipments, net		—			—			—
Recognized as revenues during period		—			(2,760,804	)		(2,760,804	)

Net deferred revenues as of September 30, 2013	$	—		$	1,288,514		$	1,288,514

Classified and reported as:
Current portion of deferred revenues	$	—		$	1,288,514		$	1,288,514
Deferred revenues, net of current portion		—			—			—

Total deferred revenues	$	—		$	1,288,514		$	1,288,514

Net deferred revenues as of October 1, 2011	$	1,652,788		$	6,138,628		$	7,791,416
Shipments, net		5,968,371			—			5,968,371
Recognized as revenues during period		(5,766,315	)		(2,089,310	)		(7,855,625	)
Recognized as a result of a change in accounting estimate(1)		(1,854,844	)		—			(1,854,844	)

Net deferred revenues as of September 30, 2012	$	—		$	4,049,318		$	4,049,318

Classified and reported as:
Current portion of deferred revenues	$	—		$	2,557,464		$	2,557,464
Deferred revenues, net of current portion		—			1,491,854			1,491,854

Total deferred revenues	$	—		$	4,049,318		$	4,049,318

(1)	The amount ultimately recognized as net product sales was approximately $1.7 million due to other discounts and allowances, including, but not limited to, rebates, chargebacks and co-pay assistance totaling approximately $191,000.